findmyKOL

Torsten Vahl, MD

Enriched profile

Assistant Professor of Medicine; Director of Translational Research; Co-Director, Structural Heart and Valve Center; Director, Left Atrial Appendage Program · Columbia University Irving Medical Center

ORCIDNPI
Region🇺🇸 New York, NY · Northeast · United StatesSpecialtyInterventional CardiologyFocusCardiology
Active KOLfindmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publication2024Online presenceverified 2026Payments2021–2025NIH fundingNone on fileWhy? →

Torsten Vahl is Assistant Professor of Medicine; Director of Translational Research; Co-Director, Structural Heart and Valve Center; Director, Left Atrial Appendage Program at Columbia University Irving Medical Center. OpenAlex indexes 247 publications with 5,894 citations (h-index 37); ClinicalTrials.gov lists 4 registered studies with this person as an investigator.

Data verified 14 Aug 2026

Overview

Updated 1 Sept 2026

Torsten Peter Vahl, MD, is Assistant Professor of Medicine at Columbia University Irving Medical Center / NewYork-Presbyterian Hospital. The public record shows 247 publications with 5,894 citations (h-index 37), centered on Cardiology. It also documents an investigator role on 4 registered clinical trials, industry payments reported by 16 companies.

  • Most recent indexed publication: 2024 · Circulation
  • Top research focus: Cardiology
  • 4 registered trials on ClinicalTrials.gov
  • Open Payments reporting from 16 companies

Generated from the cited public record · current as of 1 Sept 2026. Every fact links its source below.

Indications focus

from trials led + research topics
Aortic Valve Insufficiency3 trialsAortic Valve Disease1 trialCardiovascular Diseases1 trialAortic Valve Stenosis1 trialVascular Diseases1 trialHeart Valve Diseases1 trialConstriction, Pathologic1 trialVentricular Outflow Obstruction1 trial

Research focus

OpenAlex concept fingerprint
Cardiology

Drugs & molecules

across trials, industry payments and publications
Arcalystgeneric · RilonaceptClinical trialsIndustry payments1PublicationsEntrestogeneric · Sacubitril / valsartanClinical trialsIndustry payments1PublicationsKengrealgeneric · CangrelorClinical trialsIndustry payments1Publications

Works with

trial sponsors and companies reporting payments
JenaValve Technology, Inc.Clinical trials4Industry payments9Abbott LaboratoriesClinical trialsIndustry payments127Boston Scientific CorporationClinical trialsIndustry payments22

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
247publications

Distinct works indexed by OpenAlex, matched via ORCID; 2 in PubMed.

5,894citations

Total citations across indexed works.

37h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
4clinical trials

Investigator role on registered studies.

View trials
16companies · 2021–2025

Companies reporting payments to CMS. Facts, not judgments.

View payments
0NIH grants

Federally funded research awards.

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

Telephone

Practice address and telephone from the federal NPPES registry.

Sign in to view contact details →

Clinical trials

Updated 1 Sept 2026

Listed as an investigator on 4 registered studies on ClinicalTrials.gov. The most recent:

Industry payments

Updated 1 Sept 2026

16 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:

Medicare prescribing footprint (2020)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cardiovascular

    79.7%
    Beta blocker29.7%
    Metoprolol Succinate100%
    Part D<11 patients
    Angiotensin receptor blocker (ARB)17.6%
    Losartan Potassium100%
    Part D<11 patients
  • Blood & clotting

    20.3%
    P2Y12 inhibitor20.3%
    Clopidogrel100%
    Part D<11 patients
Where care is delivered (Part B)71.1% facility · 28.9% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →

Publications

Updated 1 Sept 2026

Their five most recent publications, matched to their ORCID record and linked to PubMed.

Online presence

Updated 1 Sept 2026

This person's own public accounts first, then places where others mention them. Two different things, listed separately.

Owned accounts

public accounts run by this person
  • Doximity

    doximity.com/pub/torsten-vahl-md

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com

Mentions by others

where others cite or feature them
  • Other

    nyevs.org/faculties/torsten-vahl-md

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →nyevs.org
  • Other

    acc.org/membership/person

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →acc.org
  • Other

    columbiacardiology.org/news/columbia-faculty-tct-2024

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →columbiacardiology.org
1 more mention behind the reveal.Reveal →

We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.

Background & recognition

Updated 1 Sept 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Education

degrees and training on record

Editorial & leadership roles

journal and society appointments
  • National Principal Investigator

    ALIGN-AR trial (JenaValve device)

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →columbiacardiology.org
  • Attending Physician

    Columbia University Irving Medical Center/NewYork-Presbyterian Hospital

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →columbiacardiology.org

Secondary affiliations

appointments beyond the home institution

Media & interviews

press, podcasts and appearances
  • Presenter

    "The Structural Heart Revolution: Perspectives From Fellowship and Beyond," TCTMD Fellows Course

    2026
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →tctmd.com

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.